Oral PrEP in adolescents in sub-Saharan Africa

Affiliations

¹ Department of Paediatrics and Child Health, University of KwaZulu-Natal, Durban 4041, South Africa; King Edward VIII Hospital, Durban, South Africa. Electronic address: archary@ukzn.ac.za.
² Enhancing Care Foundation, Durban, South Africa.

Comment

Moherndran Archary et al. Lancet Child Adolesc Health. 2020 Dec.

. 2020 Dec;4(12):854-855.

doi: 10.1016/S2352-4642(20)30340-0. Epub 2020 Oct 24.

¹ Department of Paediatrics and Child Health, University of KwaZulu-Natal, Durban 4041, South Africa; King Edward VIII Hospital, Durban, South Africa. Electronic address: archary@ukzn.ac.za.
² Enhancing Care Foundation, Durban, South Africa.

No abstract available

Comment on

Acceptability, safety, and patterns of use of oral tenofovir disoproxil fumarate and emtricitabine for HIV pre-exposure prophylaxis in South African adolescents: an open-label single-arm phase 2 trial.
Gill K, Johnson L, Dietrich J, Myer L, Marcus R, Wallace M, Pidwell T, Mendel E, Fynn L, Jones K, Wiesner L, Slack C, Strode A, Spiegel H, Hosek S, Rooney J, Gray G, Bekker LG. Gill K, et al. Lancet Child Adolesc Health. 2020 Dec;4(12):875-883. doi: 10.1016/S2352-4642(20)30248-0. Epub 2020 Oct 24. Lancet Child Adolesc Health. 2020. PMID: 33222803 Free PMC article. Clinical Trial.